
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.
Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 10, 9, 1, 52 and 29 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 8 molecules, respectively.
Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.
Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 10, 9, 1, 52 and 29 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 8 molecules, respectively.
Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
208 Pages
- Introduction
- Global Markets Direct Report Coverage
- Muscular Dystrophy – Overview
- Muscular Dystrophy – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Muscular Dystrophy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Muscular Dystrophy – Companies Involved in Therapeutics Development
- Achelios Therapeutics Inc
- Altay Therapeutics Inc
- Amicus Therapeutics Inc
- AMO Pharma Ltd
- Anima Biotech Inc
- Antisense Therapeutics Ltd
- ARMGO Pharma Inc
- Arrowhead Pharmaceuticals Inc
- ARTHEx Biotech SL
- Asklepios BioPharmaceutical Inc
- Astellas Gene Therapies
- Atamyo Therapeutics SAS
- Avidity Biosciences Inc
- Beech Tree Labs Inc
- Benitec Biopharma Inc
- Biophytis SA
- Bioprojet SCR
- CalyGene Biotechnology Inc
- CANbridge Life Sciences Ltd
- Casma Therapeutics Inc
- Celularity Inc
- Chugai Pharmaceutical Co Ltd
- Constant Therapeutics LLC
- CRISPR Therapeutics AG
- Debiopharm International SA
- Design Therapeutics Inc
- DR.Noah Biotech Inc
- Dyne Therapeutics Inc
- Edgewise Therapeutics Inc
- Elixirgen Therapeutics Inc
- Entrada Therapeutics Inc
- Enzerna Biosciences LLC
- Epicrispr Biotechnologies Inc
- EpiSwitch Rx Inc
- Exodos Life Sciences Limited Partnership
- Expansion Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Facio Therapies BV
- Faze medicines
- Fulcrum Therapeutics Inc
- Generian Pharmaceuticals Inc
- Healx Ltd
- Hope Biosciences LLC
- Juvena Therapeutics Inc
- Keros Therapeutics Inc
- LinkedUp Bioscience Inc
- Locanabio Inc
- Loqus23 Therapeutics Ltd
- Lupin Ltd
- ML Bio Solutions Inc
- Modalis Therapeutics Corp
- Myocea Inc
- Myogem Health Company SL
- NeuBase Therapeutics Inc
- Nexien Biopharma Inc
- Nippon Shinyaku Co Ltd
- Nymirum Inc
- Pasithea Therapeutics Corp
- Pepgen Inc
- Pfizer Inc
- Phrixus Pharmaceuticals Inc
- Prothelia Inc
- QiXia Decode Therapeutics
- Recursion Pharmaceuticals Inc
- SanBio Co Ltd
- Sanofi
- Santhera Pharmaceuticals Holding AG
- Sarcomed AB
- Sarepta Therapeutics Inc
- Scriptr Global Inc
- SEAL Therapeutics AG
- Seelos Therapeutics, Inc.
- Siwa Therapeutics Inc
- Syros Pharmaceuticals Inc
- Triplet Therapeutics Inc
- Vertex Pharmaceuticals Inc
- Vita Therapeutics Inc
- Xonovo Inc
- Muscular Dystrophy – Drug Profiles
- alisporivir – Drug Profile
- alpha-tocopherol – Drug Profile
- Antisense Oligonucleotide to Inhibit DUX4 for Facioscapulohumeral Muscular Dystrophy – Drug Profile
- Antisense RNAi Oligonucleotide to Inhibit DUX4 for Facioscapulohumeral Muscular Dystrophy – Drug Profile
- AOC-1001 – Drug Profile
- AOC-1020 – Drug Profile
- ARM-210 – Drug Profile
- ARODUX-4 – Drug Profile
- ARTHEx-01 – Drug Profile
- AT-466 – Drug Profile
- ATA-100 – Drug Profile
- ATA-200 – Drug Profile
- ATL-1102 – Drug Profile
- BB-301 – Drug Profile
- BIO-103 – Drug Profile
- Calpain 3 – Drug Profile
- Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology – Drug Profile
- CG-10052 – Drug Profile
- CIP-137401 – Drug Profile
- CRI-007 – Drug Profile
- DM – Drug Profile
- DM1 Program – Drug Profile
- domagrozumab – Drug Profile
- Drugs for Myotonic Dystrophy – Drug Profile
- DYNE-101 – Drug Profile
- Dyne-102 – Drug Profile
- DYNE-301 – Drug Profile
- EDG-5506 – Drug Profile
- Emery-Dreifuss muscular dystrophy Type 1 – Drug Profile
- ENTR-701 – Drug Profile
- ENZ-003 – Drug Profile
- EPIC-321 – Drug Profile
- ERX-963 – Drug Profile
- erythromycin – Drug Profile
- Facioscapulohumeral Muscular Dystrophy (FSHD) – Drug Profile
- FM-10 – Drug Profile
- Gene Therapies for Friedreich Ataxia and Myotonic Dystrophy – Drug Profile
- Gene Therapy for Genetic Disorders, Neurology, Musculoskeletal and Ophthalmology – Drug Profile
- Gene Therapy for Muscular Dystrophy – Drug Profile
- Gene Therapy for Myotonic Dystrophy – Drug Profile
- Gene Therapy to Activate DMPK for Myotonic Dystrophy Type 1 – Drug Profile
- Gene Therapy to Activate Dystrophin for Muscular Dystrophy – Drug Profile
- Gene Therapy to Activate ZSCAN4 for Muscular Dystrophy – Drug Profile
- Gene Therapy To Inhibit DMPK for Myotonic Dystrophy – Drug Profile
- Gene Therapy to Target LAMA2 for Congenital Muscular Dystrophy – Drug Profile
- GNT-0008 – Drug Profile
- IP-300W – Drug Profile
- IUCT-169 – Drug Profile
- IUCT-290 – Drug Profile
- IUCT-309 – Drug Profile
- JM-642 – Drug Profile
- JUV-161 – Drug Profile
- KER-050 – Drug Profile
- ketoprofen – Drug Profile
- LGMD2B – Drug Profile
- LION-101 – Drug Profile
- losmapimod – Drug Profile
- LR-08 – Drug Profile
- LUB-002 – Drug Profile
- MCDX-4 – Drug Profile
- MD-1 – Drug Profile
- MDL-101 – Drug Profile
- mexiletine hydrochloride – Drug Profile
- Myotonic Dystrophy Type 1 – Drug Profile
- N/D FSHD – Drug Profile
- nandrolone decanoate – Drug Profile
- Next-Generation Research Programs – Drug Profile
- NS-035 – Drug Profile
- NT-0200 – Drug Profile
- NT-0231.F – Drug Profile
- PDA-002 – Drug Profile
- PGN-EDODM1 – Drug Profile
- pitolisant hydrochloride – Drug Profile
- poloxamer – Drug Profile
- rebastinib – Drug Profile
- RG-6237 – Drug Profile
- RHLAM-111 – Drug Profile
- ribitol – Drug Profile
- RNAi Gene Therapy to Inhibit DUX4 for Facioscapulohumeral Muscular Dystrophy – Drug Profile
- RNAi Gene Therapy to Inhibit Myotilin for LGMD – Drug Profile
- RP-33 – Drug Profile
- SB-308 – Drug Profile
- SIWA-318 – Drug Profile
- Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain – Drug Profile
- Small Molecule to Inhibit DMPK for Myotonic Dystrophy – Drug Profile
- Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 – Drug Profile
- Small Molecule to Target RNA for Myotonic Dystrophy Type 1 – Drug Profile
- Small Molecules for Emery-Dreifuss Muscular Dystrophy – Drug Profile
- Small Molecules for Huntington Disease, Genetic Disorders and Myotonic Dystrophy – Drug Profile
- Small Molecules for Laminin-Deficient Congenital Muscular Dystrophy – Drug Profile
- Small Molecules for Muscular Dystrophy – Drug Profile
- Small Molecules for Myotonic Dystrophy – Drug Profile
- Small Molecules for Myotonic Dystrophy Type 2 – Drug Profile
- Small Molecules to Activate AMPK for Glomerulonephritis, Polycystic Kidney Disease, Myotonic Dystrophy and Mitochondrial Diseases – Drug Profile
- Small Molecules to Activate FKRP for Limb-Girdle Muscular Dystrophy – Drug Profile
- Small Molecules to Activate SMCHD1 for Facioscapulohumeral Muscular Dystrophy – Drug Profile
- Small Molecules to Agonize CB1 and CB2 for Myotonic Dystrophy and Myotonia – Drug Profile
- Small Molecules to Agonize TRPML1 for Muscular Dystrophy – Drug Profile
- Small Molecules to Inhibit CNBP for Myotonic Dystrophy Type 2 – Drug Profile
- Small Molecules to Inhibit DMPK for Myotonic Dystrophy Type 1 – Drug Profile
- Small Molecules to Target RNA for Myotonic Dystrophy – Drug Profile
- SRP-6004 – Drug Profile
- SRP-9003 – Drug Profile
- SRP-9004 – Drug Profile
- SRP-9005 – Drug Profile
- SRP-9006 – Drug Profile
- Synthetic Peptides to Inhibit Tcp for Neurodegenerative Disorders, Muscular Dystrophy and Oncology – Drug Profile
- tideglusib – Drug Profile
- trehalose – Drug Profile
- tRNA Enzyme Pairs – Drug Profile
- TTX-3360 – Drug Profile
- TXA-127 – Drug Profile
- vamorolone – Drug Profile
- VTA-100 – Drug Profile
- VTA-120 – Drug Profile
- VTA-200 – Drug Profile
- XN-001 – Drug Profile
- Muscular Dystrophy – Dormant Projects
- Muscular Dystrophy – Discontinued Products
- Muscular Dystrophy – Product Development Milestones
- Featured News & Press Releases
- Oct 14, 2022: Avidity Biosciences announces upcoming presentation on AOC-1001 at 27th International Hybrid Annual Congress of World Muscle Society
- Sep 28, 2022: FDA places partial hold on Avidity’s Phase I/II myotonic dystrophy trial
- Sep 27, 2022: Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
- Aug 04, 2022: Entrada Therapeutics announces collaboration with the Myotonic Dystrophy Clinical Research Network to study the natural history of myotonic dystrophy type 1
- Aug 02, 2022: Avidity Biosciences enrolls patients in the MARINA open-label extension study
- Jul 13, 2022: Fulcrum phase 3 FSHD clinical trial using AMRA Medical's Whole-body MRI Measurements as a Key Secondary Endpoint
- Jul 12, 2022: Dyne Therapeutics announces clearance of clinical trial application for DYNE-101 for the treatment of myotonic dystrophy type 1
- Jul 05, 2022: Fulcrum Therapeutics enrolls first patient in pivotal global Phase 3 clinical trial of Losmapimod for facioscapulohumeral muscular dystrophy (FSHD)
- Jun 20, 2022: New muscle disease indication for ATL1102 – Limb girdle muscular dystrophy R2
- May 17, 2022: NeuBase presents new preclinical data at ASGCT 2022 for its DM1 program demonstrating wide tissue distribution and supporting a differentiated whole-body treatment solution
- May 16, 2022: Dyne Therapeutics presents new in vivo data from DYNE-101 at ASGCT Annual Meeting demonstrating low monthly dosing leads to robust DMPK RNA knockdown
- May 16, 2022: Atamyo Therapeutics announces significant for ATA-100 to treat Limb-Girdle Muscular Dystrophy 2I/R9
- May 11, 2022: Entrada Therapeutics presents new data supporting its growing pipeline of Endosomal Escape Vehicle (EEV™) therapeutics, including ENTR-701 at TIDES USA 2022
- May 02, 2022: NeuBase Therapeutics announces presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Muscular Dystrophy, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Companies, 2022 (Contd..4)
- Table 12: Products under Development by Companies, 2022 (Contd..5)
- Table 13: Products under Development by Companies, 2022 (Contd..6)
- Table 14: Products under Development by Universities/Institutes, 2022
- Table 15: Number of Products by Stage and Target, 2022
- Table 16: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 17: Number of Products by Stage and Mechanism of Action, 2022
- Table 18: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 19: Number of Products by Stage and Route of Administration, 2022
- Table 20: Number of Products by Stage and Molecule Type, 2022
- Table 21: Muscular Dystrophy – Pipeline by Achelios Therapeutics Inc, 2022
- Table 22: Muscular Dystrophy – Pipeline by Altay Therapeutics Inc, 2022
- Table 23: Muscular Dystrophy – Pipeline by Amicus Therapeutics Inc, 2022
- Table 24: Muscular Dystrophy – Pipeline by AMO Pharma Ltd, 2022
- Table 25: Muscular Dystrophy – Pipeline by Anima Biotech Inc, 2022
- Table 26: Muscular Dystrophy – Pipeline by Antisense Therapeutics Ltd, 2022
- Table 27: Muscular Dystrophy – Pipeline by ARMGO Pharma Inc, 2022
- Table 28: Muscular Dystrophy – Pipeline by Arrowhead Pharmaceuticals Inc, 2022
- Table 29: Muscular Dystrophy – Pipeline by ARTHEx Biotech SL, 2022
- Table 30: Muscular Dystrophy – Pipeline by Asklepios BioPharmaceutical Inc, 2022
- Table 31: Muscular Dystrophy – Pipeline by Astellas Gene Therapies, 2022
- Table 32: Muscular Dystrophy – Pipeline by Atamyo Therapeutics SAS, 2022
- Table 33: Muscular Dystrophy – Pipeline by Avidity Biosciences Inc, 2022
- Table 34: Muscular Dystrophy – Pipeline by Beech Tree Labs Inc, 2022
- Table 35: Muscular Dystrophy – Pipeline by Benitec Biopharma Inc, 2022
- Table 36: Muscular Dystrophy – Pipeline by Biophytis SA, 2022
- Table 37: Muscular Dystrophy – Pipeline by Bioprojet SCR, 2022
- Table 38: Muscular Dystrophy – Pipeline by CalyGene Biotechnology Inc, 2022
- Table 39: Muscular Dystrophy – Pipeline by CANbridge Life Sciences Ltd, 2022
- Table 40: Muscular Dystrophy – Pipeline by Casma Therapeutics Inc, 2022
- Table 41: Muscular Dystrophy – Pipeline by Celularity Inc, 2022
- Table 42: Muscular Dystrophy – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
- Table 43: Muscular Dystrophy – Pipeline by Constant Therapeutics LLC, 2022
- Table 44: Muscular Dystrophy – Pipeline by CRISPR Therapeutics AG, 2022
- Table 45: Muscular Dystrophy – Pipeline by Debiopharm International SA, 2022
- Table 46: Muscular Dystrophy – Pipeline by Design Therapeutics Inc, 2022
- Table 47: Muscular Dystrophy – Pipeline by DR.Noah Biotech Inc, 2022
- Table 48: Muscular Dystrophy – Pipeline by Dyne Therapeutics Inc, 2022
- Table 49: Muscular Dystrophy – Pipeline by Edgewise Therapeutics Inc, 2022
- Table 50: Muscular Dystrophy – Pipeline by Elixirgen Therapeutics Inc, 2022
- Table 51: Muscular Dystrophy – Pipeline by Entrada Therapeutics Inc, 2022
- Table 52: Muscular Dystrophy – Pipeline by Enzerna Biosciences LLC, 2022
- Table 53: Muscular Dystrophy – Pipeline by Epicrispr Biotechnologies Inc, 2022
- Table 54: Muscular Dystrophy – Pipeline by EpiSwitch Rx Inc, 2022
- Table 55: Muscular Dystrophy – Pipeline by Exodos Life Sciences Limited Partnership, 2022
- Table 56: Muscular Dystrophy – Pipeline by Expansion Therapeutics Inc, 2022
- Table 57: Muscular Dystrophy – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 58: Muscular Dystrophy – Pipeline by Facio Therapies BV, 2022
- Table 59: Muscular Dystrophy – Pipeline by Faze medicines, 2022
- Table 60: Muscular Dystrophy – Pipeline by Fulcrum Therapeutics Inc, 2022
- Table 61: Muscular Dystrophy – Pipeline by Generian Pharmaceuticals Inc, 2022
- Table 62: Muscular Dystrophy – Pipeline by Healx Ltd, 2022
- Table 63: Muscular Dystrophy – Pipeline by Hope Biosciences LLC, 2022
- Table 64: Muscular Dystrophy – Pipeline by Juvena Therapeutics Inc, 2022
- Table 65: Muscular Dystrophy – Pipeline by Keros Therapeutics Inc, 2022
- Table 66: Muscular Dystrophy – Pipeline by LinkedUp Bioscience Inc, 2022
- Table 67: Muscular Dystrophy – Pipeline by Locanabio Inc, 2022
- Table 68: Muscular Dystrophy – Pipeline by Loqus23 Therapeutics Ltd, 2022
- Table 69: Muscular Dystrophy – Pipeline by Lupin Ltd, 2022
- Table 70: Muscular Dystrophy – Pipeline by ML Bio Solutions Inc, 2022
- Table 71: Muscular Dystrophy – Pipeline by Modalis Therapeutics Corp, 2022
- Table 72: Muscular Dystrophy – Pipeline by Myocea Inc, 2022
- Table 73: Muscular Dystrophy – Pipeline by Myogem Health Company SL, 2022
- Table 74: Muscular Dystrophy – Pipeline by NeuBase Therapeutics Inc, 2022
- Table 75: Muscular Dystrophy – Pipeline by Nexien Biopharma Inc, 2022
- Table 76: Muscular Dystrophy – Pipeline by Nippon Shinyaku Co Ltd, 2022
- Table 77: Muscular Dystrophy – Pipeline by Nymirum Inc, 2022
- Table 78: Muscular Dystrophy – Pipeline by Pasithea Therapeutics Corp, 2022
- Table 79: Muscular Dystrophy – Pipeline by Pepgen Inc, 2022
- Table 80: Muscular Dystrophy – Pipeline by Pfizer Inc, 2022
- Table 81: Muscular Dystrophy – Pipeline by Phrixus Pharmaceuticals Inc, 2022
- Table 82: Muscular Dystrophy – Pipeline by Prothelia Inc, 2022
- Table 83: Muscular Dystrophy – Pipeline by QiXia Decode Therapeutics, 2022
- Table 84: Muscular Dystrophy – Pipeline by Recursion Pharmaceuticals Inc, 2022
- Table 85: Muscular Dystrophy – Pipeline by SanBio Co Ltd, 2022
- Table 86: Muscular Dystrophy – Pipeline by Sanofi, 2022
- Table 87: Muscular Dystrophy – Pipeline by Santhera Pharmaceuticals Holding AG, 2022
- Table 88: Muscular Dystrophy – Pipeline by Sarcomed AB, 2022
- Table 89: Muscular Dystrophy – Pipeline by Sarepta Therapeutics Inc, 2022
- Table 90: Muscular Dystrophy – Pipeline by Scriptr Global Inc, 2022
- Table 91: Muscular Dystrophy – Pipeline by SEAL Therapeutics AG, 2022
- Table 92: Muscular Dystrophy – Pipeline by Seelos Therapeutics, Inc., 2022
- Table 93: Muscular Dystrophy – Pipeline by Siwa Therapeutics Inc, 2022
- Table 94: Muscular Dystrophy – Pipeline by Syros Pharmaceuticals Inc, 2022
- Table 95: Muscular Dystrophy – Pipeline by Triplet Therapeutics Inc, 2022
- Table 96: Muscular Dystrophy – Pipeline by Vertex Pharmaceuticals Inc, 2022
- Table 97: Muscular Dystrophy – Pipeline by Vita Therapeutics Inc, 2022
- Table 98: Muscular Dystrophy – Pipeline by Xonovo Inc, 2022
- Table 99: Muscular Dystrophy – Dormant Projects, 2022
- Table 100: Muscular Dystrophy – Dormant Projects, 2022 (Contd..1)
- Table 101: Muscular Dystrophy – Dormant Projects, 2022 (Contd..2)
- Table 102: Muscular Dystrophy – Dormant Projects, 2022 (Contd..3)
- Table 103: Muscular Dystrophy – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Muscular Dystrophy, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.